Sample size for a noninferiority clinical trial with time-to-event data in the presence of competing risks

被引:2
|
作者
Han, Dong [1 ,2 ]
Chen, Zheng [1 ]
Hou, Yawen [3 ]
机构
[1] Southern Med Univ, Sch Publ Hlth, Dept Biostat, Guangdong Prov Key Lab Trop Dis Res, Guangzhou, Guangdong, Peoples R China
[2] Southern Med Univ, Dept Qual Control, Affiliated Hosp 3, Guangzhou, Guangdong, Peoples R China
[3] Jinan Univ, Dept Stat, Coll Econ, Guangzhou, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Competing risks; Noninferiority clinical trials; sample size; sub-distribution hazard ratio; survival data; END-POINTS; MULTISTATE MODELS; FOLLOW-UP; PITFALLS; CANCER;
D O I
10.1080/10543406.2017.1399897
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The analysis and planning methods for competing risks model have been described in the literature in recent decades, and noninferiority clinical trials are helpful in current pharmaceutical practice. Analytical methods for noninferiority clinical trials in the presence of competing risks (NiCTCR) were investigated by Parpia et al., who indicated that the proportional sub-distribution hazard (SDH) model is appropriate in the context of biological studies. However, the analytical methods of the competing risks model differ from those appropriate for analyzing noninferiority clinical trials with a single outcome; thus, a corresponding method for planning such trials is necessary. A sample size formula for NiCTCR based on the proportional SDH model is presented in this paper. The primary endpoint relies on the SDH ratio. A total of 120 simulations and an example based on a randomized controlled trial verified the empirical performance of the presented formula. The results demonstrate that the empirical power of sample size formulas based on the Weibull distribution for noninferiority clinical trials with competing risks can reach the targeted power.
引用
收藏
页码:797 / 807
页数:11
相关论文
共 50 条
  • [41] Discrimination-based sample size calculations for multivariable prognostic models for time-to-event data
    Rachel C. Jinks
    Patrick Royston
    Mahesh KB Parmar
    [J]. BMC Medical Research Methodology, 15
  • [42] Minimum sample size calculations for external validation of a clinical prediction model with a time-to-event outcome
    Riley, Richard D.
    Collins, Gary S.
    Ensor, Joie
    Archer, Lucinda
    Booth, Sarah
    Mozumder, Sarwar, I
    Rutherford, Mark J.
    van Smeden, Maarten
    Lambert, Paul C.
    Snell, Kym I. E.
    [J]. STATISTICS IN MEDICINE, 2022, 41 (07) : 1280 - 1295
  • [43] Sample size calculation for cluster randomization trials with a time-to-event endpoint
    Li, Jianghao
    Jung, Sin-Ho
    [J]. STATISTICS IN MEDICINE, 2020, 39 (25) : 3608 - 3623
  • [44] Sample Size Determination and Rational Partition for A Multi- Regional Trial for Survival (Time-To-Event) Data with Unrecognized Heterogeneity that Interacts with Treatment
    Ko, Feng-Shou
    [J]. COMMUNICATIONS IN STATISTICS-THEORY AND METHODS, 2015, 44 (03) : 486 - 496
  • [45] Using the geometric average hazard ratio in sample size calculation for time-to-event data with composite endpoints
    Jordi Cortés Martínez
    Ronald B. Geskus
    KyungMann Kim
    Guadalupe Gómez Melis
    [J]. BMC Medical Research Methodology, 21
  • [46] Using the geometric average hazard ratio in sample size calculation for time-to-event data with composite endpoints
    Martinez, Jordi Cortes
    Geskus, Ronald B.
    Kim, Kyung Mann
    Melis, Guadalupe Gomez
    [J]. BMC MEDICAL RESEARCH METHODOLOGY, 2021, 21 (01)
  • [47] Sample size determination in superiority or non-inferiority clinical trials with time-to-event data under exponential, Weibull and Gompertz distributions
    Han, Dong
    Hou, Yawen
    Ou, Chunquan
    Chen, Zheng
    [J]. COMMUNICATIONS IN STATISTICS-SIMULATION AND COMPUTATION, 2023, 52 (04) : 1212 - 1224
  • [48] Simulating time-to-event data from parametric distributions, custom distributions, competing-risks models, and general multistate models
    Crowther, Michael J.
    [J]. STATA JOURNAL, 2022, 22 (01): : 3 - 24
  • [49] Analyzing time-to-event data in a clinical trial when an unknown proportion of subjects has experienced the event at entry
    Balasubramanian, R
    Lagakos, SW
    [J]. BIOMETRICS, 2004, 60 (02) : 335 - 343
  • [50] A semiparametric Bayesian approach to population finding with time-to-event and toxicity data in a randomized clinical trial
    Morita, Satoshi
    Mueller, Peter
    Abe, Hiroyasu
    [J]. BIOMETRICS, 2021, 77 (02) : 634 - 648